CRISPR Therapeutics AG (NASDAQ:CRSP) has a beta value of 1.74 and has seen 1.98 million shares traded in the last trading session. The company, currently valued at $3.63B, closed the last trade at $42.37 per share which meant it lost -$0.97 on the day or -2.24% during that session. The CRSP stock price is -87.23% off its 52-week high price of $79.33 and 13.81% above the 52-week low of $36.52.
The consensus among analysts is that CRISPR Therapeutics AG (CRSP) is Buy stock at the moment, with a recommendation rating of 1.97. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 8 have rated it as a Hold, with 6 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -1.28.
CRISPR Therapeutics AG (NASDAQ:CRSP) trade information
Sporting -2.24% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the CRSP stock price touched $42.37 or saw a rise of 8.03%. Year-to-date, CRISPR Therapeutics AG shares have moved 7.65%, while the 5-day performance has seen it change -2.49%. Over the past 30 days, the shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have changed 6.70%.
Wall Street analysts have a consensus price target for the stock at $67, which means that the shares’ value could jump 36.76% from current levels. The projected low price target is $65.0 while the price target rests at a high of $95.0. In that case, then, we find that the current price level is -124.22% off the targeted high while a plunge would see the stock gain -53.41% from current levels.
CRISPR Therapeutics AG (CRSP) estimates and forecasts
The company’s shares have lost -5.04% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 54.70%.
15 analysts offering their estimates for the company have set an average revenue estimate of 6.36M for the current quarter. 15 have an estimated revenue figure of 9.15M for the next ending quarter. Year-ago sales stood 504k and 517k respectively for this quarter and the next, and analysts expect sales will grow by 1,162.84% for the current quarter and 54.70% for the next.
Earnings growth for 2025 is a modest -10.94% while over the next 5 years, the company’s earnings are expected to increase by 15.85%.
CRSP Dividends
CRISPR Therapeutics AG is expected to release its next earnings report in April this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
CRISPR Therapeutics AG (NASDAQ:CRSP)’s Major holders
The top two institutional holders are CAPITAL INTERNATIONAL INVESTORS with over 7.87 million shares worth more than $424.8 million. As of 2024-06-30, CAPITAL INTERNATIONAL INVESTORS held 9.2619% of shares outstanding.
The other major institutional holder is ARK INVESTMENT MANAGEMENT LLC, with the holding of over 7.78 million shares as of 2024-06-30. The firm’s total holdings are worth over $420.12 million and represent 9.1597% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are ARK ETF Tr-ARK Innovation ETF and New Perspective Fund Inc . As of Dec 31, 2024 , the former fund manager holds about 7.50% shares in the company for having 6.44 shares of worth $272.73 million while later fund manager owns 4.79 shares of worth $203.0 million as of Dec 31, 2024 , which makes it owner of about 5.59% of company’s outstanding stock.
